Amyris Charts a New Course Following Bankruptcy Restructuring

Having emerged from Chapter 11 bankruptcy proceedings in May 2024, Amyris has completed its transition to a privately held entity. This restructuring involved the cancellation of all previously outstanding common stock, resulting in a total loss for former equity holders. The company is now directing its efforts exclusively toward the research, development, and commercialization of sustainable, bio-fermented ingredients. The central question is whether this sharpened focus on core technological strengths can drive a successful long-term recovery.

A critical component of the operational turnaround is the expansion of manufacturing capacity. The facility in Barra Bonita, Brazil, is pivotal to this effort. Preparations were finalized there to bring a fourth precision fermentation production line online, with commissioning targeted for the beginning of the current year.

This expansion is designed to substantially boost output of specialty ingredients and solidify the firm's standing in the synthetic biology sector. The production leverages Amyris's proprietary fermentation platform, which facilitates the efficient manufacture of complex molecules.

Should investors sell immediately? Or is it worth buying Amyris?

A Strategic Framework for Growth

The long-term roadmap is defined by the "Strategy 2030" plan, adopted in November 2024. Its objective is to reposition the company within the expanding market for sustainable chemistry. Demand for eco-friendly alternatives remains robust across key segments including clean beauty, health, and flavors & fragrances.

For company observers, the execution of this plan will be the primary focus in the coming months. A key determinant of success will be the speed at which technological advancements can be converted into commercially scalable products, allowing Amyris to compete effectively in the intense biotechnology landscape. Particular attention will be paid to achieving full, on-schedule utilization of the new Brazilian production capabilities.

• The restructuring process concluded in May 2024.
• All existing common shares were annulled.
• The focus is now on precision fermentation and operational efficiency.
• The Strategy 2030 plan provides the operational framework.